Morgan Stanley Maintains Equal-Weight on Rhythm Pharmaceuticals, Raises Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $26 to $28.
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $45
Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $40 to $45.
Ladenburg Thalmann Reiterates Buy on Rhythm Pharmaceuticals, Maintains $35 Price Target
Ladenburg Thalmann analyst Michael Higgins reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $35 price target.
Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $32 Price Target
Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $32 price target.
Rhythm Pharmaceuticals Q4 EPS $(0.75) Beats $(0.81) Estimate, Sales $8.79 Miss $7.03M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 11.76 percent increase over losses of $(0.85) per share
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Rhythm Pharmaceuticals Acquires Xinvento, A Netherlands-based Biotech Company Focused On Developing Therapies For Congenital Hyperinsulinism For $5M Upfront
According to the terms of the acquisition agreement, Rhythm B.V. will purchase 100 percent of Xinvento’s fully-diluted equity for an upfront payment of $5 million (subject to customary adjustments) with an
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $35
Goldman Sachs analyst Graig Suvannavejh maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $31 to $35.
Morgan Stanley Maintains Equal-Weight on Rhythm Pharmaceuticals, Raises Price Target to $26
Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $16 to $26.